Bibliography
- Franks S : Diagnosis of polycystic ovarian syndrome: In defense of the Rotterdam criteria.J. Clin. Endocrinol. Metab.91(3) , 786–789 (2006).
- The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril.81(1) , 19–25 (2004).
- Azziz R , CarminaE, DewaillyD et al.: The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.Fertil. Steril.91(2) , 456–488 (2009).
- Homburg R : The management of infertility associated with polycystic ovary syndrome.Reprod. Biol. Endocrinol.1 , 109 (2003).
- Fauser BCJM , DiedrichK, DevroeyP, on behalf of the Evian Annual Reproduction (EVAR) Workshop Group: Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum. Reprod. Update14(1) , 1–14 (2008).
- Ghobadi C , NguyenTH, LennardMS, AmerS, Rostami-HodjeganA, LedgerWL: Evaluation of an existing nomogram for predicting the response to clomiphene citrate.Fertil. Steril.87(3) , 597–602 (2007).
- Imani B , EijkemansMJ, te Velde ER, Habbema JD, Fauser BC: Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J. Clin. Endocrinol. Metab.83(7) , 2361–2365 (1998).
- Imani B , EijkemansMJ, de Jong FH et al.: Free androgen index and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J. Clin. Endocrinol. Metab.85(2) , 676–682 (2000).
- Kurabayashi T , SuzukiM, FujitaK, MurakawaH, HasegawaI, TanakaK: Prognostic factors for ovulatory response with clomiphene citrate in polycystic ovary syndrome.Eur. J. Obstet. Gynecol. Reprod. Biol.126(2) , 201–205 (2006).
- Palomba S , FalboA, OrioJ, TolinoA, ZulloF: Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome.Fertil. Steril.91(6) , 2557–2567 (2009).
- Perez MM , GromollJ, BehreHM, GassnerC, NieschlagE, SimoniM: Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype.J. Clin. Endocrinol. Metab.85(9) , 3365–3369 (2000).
- Behre HM , GrebRR, MempelA et al.: Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation.Pharmacogenet. Genomics15(7) , 451–456 (2005).
- Daelemans C , SmitsG, de Maertelaer V et al.: Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. J. Clin. Endocrinol. Metab.89(12) , 6310–6315 (2004).
- de Castro F , RuizR, MontoroL et al.: Role of follicle-stimulating hormone receptor Ser680Asn polymorphism in the efficacy of follicle-stimulating hormone.Fertil. Steril.80(3) , 571–576 (2003).
- de Castro F , MoronFJ, MontoroL, RealLM, RuizA: Pharmacogenetics of controlled ovarian hyperstimulation.Pharmacogenomics6(6) , 629–637 (2005).
- Douchi T , OkiT, YamasakiH, NakaeM, ImabayashiA, NagataY: Body fat patterning in polycystic ovary syndrome women as a predictor of the response to clomiphene.Acta Obstet. Gynecol. Scand.83(9) , 838–841 (2004).
- Jun JK , YoonJS, KuSY et al.: Follicle-stimulating hormone receptor gene polymorphism and ovarian responses to controlled ovarian hyperstimulation for IVF-ET.J. Hum. Genet.51(8) , 665–670 (2006).
- Klinkert ER , te Velde ER, Weima S et al.: FSH receptor genotype is associated with pregnancy but not with ovarian response in IVF. Reprod. Biomed. Online13(5) , 687–695 (2006).
- Loutradis D , PatsoulaE, MinasV et al.: FSH receptor gene polymorphisms have a role for different ovarian response to stimulation in patients entering IVF/ICSI-ET programs.J. Assist. Reprod. Genet.23(4) , 177–184 (2006).
- Overbeek A , KuijperEA, HendriksML et al.: Clomiphene citrate resistance in relation to follicle-stimulating hormone receptor Ser680Ser-polymorphism in polycystic ovary syndrome.Hum. Reprod.24(8) , 2007–2013 (2009).
- Valkenburg O , van Santbrink EJP, Themmen APN, Uitterlinden AG, Fauser BC, Laven JSE: FSH receptor polymorphism affects the outcome of ovulation induction in normogonadotropic anovulatory infertility (WHOII). Hum. Reprod.24(Suppl. 1) , I85 (2009).
- Brauch H , MurdterTE, EichelbaumM, SchwabM: Pharmacogenomics of tamoxifen therapy.Clin. Chem. (2009) (Epub ahead of print).
- Overbeek A , LambalkCB: Phenotypic and pharmacogenetic aspects of ovulation induction in WHO II anovulatory women.Gynecol. Endocrinol.25(4) , 222–234 (2009).
- Shu Y , BrownC, CastroRA et al.: Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.Clin. Pharmacol. Ther.83(2) , 273–280 (2008).
- Legro RS , BarnhartHX, SchlaffWD et al.: Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene.J. Clin. Endocrinol. Metab.93(3) , 792–800 (2008).